DM2 targeting antisense peptide nucleic acid
/ NeuBase Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 31, 2020
NeuBase Therapeutics announces positive, preclinical data validating its novel genetic therapy Patrol platform
(GlobeNewswire, NeuBase Therapeutics, Inc.)
- "NeuBase Therapeutics, Inc....today announced positive preclinical data from its pharmacokinetics studies in non-human primates ('NHPs') and in vitro pharmacodynamics data in patient-derived cell lines. NeuBase believes these data validate the key advantages of the proprietary NeuBase peptide-nucleic acid (“PNA”) antisense oligonucleotide (PATrOL™) platform and support the Company’s decision to advance the development of its Huntington’s disease ('HD') and myotonic dystrophy type 1 ('DM1') programs....The Company’s plans to commence clinical trials in Huntington’s disease and myotonic dystrophy type 1..."
New trial • PK/PD data • Preclinical
1 to 1
Of
1
Go to page
1